{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:13:03Z","timestamp":1794103983017,"version":"4.8.0"},"reference-count":29,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The BCL6-corepressor (BCOR) is a tumor-suppressor gene located on the short arm of chromosome X. Data are limited regarding factors predicting survival in BCOR-mutated (mBCOR) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We evaluated 138 patients with mBCOR myeloid disorders, of which 36 (26.1%) had AML and 63 (45.6%) had MDS. Sixty-six (47.8%) patients had a normal karyotype while 18 (13%) patients had complex karyotype. BCOR-mutated MDS\/AML were highly associated with RUNX1 and U2AF1 co-mutations. In contrast, TP53 mutation was infrequently seen with mBCOR MDS. Patients with an isolated BCOR mutation had similar survival compared to those with high-risk co-mutations by European LeukemiaNet (ELN) 2022 criteria (median OS 1.16 vs. 1.27 years, P=0.46). Complex karyotype adversely impacted survival among mBCOR AML\/MDS (HR 4.12, P&lt;0.001), while allogeneic stem cell transplant (alloSCT) improved survival (HR 0.38, P=0.04). However, RUNX1 co-mutation was associated with an increased risk of post-alloSCT relapse (HR 88.0, P=0.02), whereas melphalan-based conditioning was associated with a decreased relapse risk (HR 0.02, P=0.01). We conclude that mBCOR is a high-risk feature across MDS\/AML, and that alloSCT improves survival in this population.<\/jats:p>","DOI":"10.3324\/haematol.2023.284185","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T05:38:12Z","timestamp":1706765892000},"page":"1779-1791","source":"Crossref","is-referenced-by-count":7,"title":["Genetic landscape and clinical outcomes of patients with &lt;i&gt;BCOR&lt;\/i&gt; mutated myeloid neoplasms"],"prefix":"10.3324","volume":"109","author":[{"given":"Anmol","family":"Baranwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Basmaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahga","family":"Katamesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Viswanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Arana","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"61875","doi-asserted-by":"crossref","unstructured":"Sportoletti P, Sorcini D, Falini B. BCOR gene alterations in hematologic diseases. Blood. 2021; 138(24):2455-2468.","DOI":"10.1182\/blood.2021010958"},{"key":"61876","doi-asserted-by":"crossref","unstructured":"Grossmann V, Tiacci E, Holmes AB. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011; 118(23):6153-6163.","DOI":"10.1182\/blood-2011-07-365320"},{"key":"61877","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"61878","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23):2209-2221.","DOI":"10.1056\/NEJMoa1516192"},{"key":"61879","doi-asserted-by":"crossref","unstructured":"Gardin C, Pautas C, Fournier E. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. Blood Adv. 2020; 4(9):1942-1949.","DOI":"10.1182\/bloodadvances.2019001349"},{"key":"61880","doi-asserted-by":"crossref","unstructured":"Damm F, Chesnais V, Nagata Y. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013; 122(18):3169-3177.","DOI":"10.1182\/blood-2012-11-469619"},{"key":"61881","doi-asserted-by":"crossref","unstructured":"Abuhadra N, Mukherjee S, Al-Issa K. BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. Leuk Lymphoma. 2019; 60(6):1587-1590.","DOI":"10.1080\/10428194.2018.1543885"},{"key":"61882","doi-asserted-by":"crossref","unstructured":"Haferlach T, Nagata Y, Grossmann V. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241-247.","DOI":"10.1038\/leu.2013.336"},{"key":"61883","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-2405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"61884","doi-asserted-by":"crossref","unstructured":"Greenberg PL, Tuechler H, Schanz J. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012; 120(12):2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"61885","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"61886","doi-asserted-by":"crossref","unstructured":"Bacigalupo A, Ballen K, Rizzo D. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628-1633.","DOI":"10.1016\/j.bbmt.2009.07.004"},{"key":"61887","doi-asserted-by":"crossref","unstructured":"Glucksberg H, Storb R, Fefer A. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295-304.","DOI":"10.1097\/00007890-197410000-00001"},{"key":"61888","doi-asserted-by":"crossref","unstructured":"Jagasia MH, Greinix HT, Arora M. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2015; 21(3):389-401.","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"61889","unstructured":"Aragon TJ, Fay MP, Wollschlaeger D, Omidpanah A. Epitools: epidemiology tools. R package version 0.5-10.1. 2020."},{"key":"61890","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"61891","doi-asserted-by":"crossref","unstructured":"Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991; 9(1):191-192.","DOI":"10.1200\/JCO.1991.9.1.191"},{"key":"61892","doi-asserted-by":"crossref","unstructured":"Moore DF. Applied survival analysis using R. 2016.","DOI":"10.1007\/978-3-319-31245-3"},{"key":"61893","unstructured":"R Core Team. R: a language and environment for statistical computing. 2023."},{"key":"61894","doi-asserted-by":"crossref","unstructured":"Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize implements and enhances circular visualization in R. Bioinformatics. 2014; 30(19):2811-2812.","DOI":"10.1093\/bioinformatics\/btu393"},{"key":"61895","doi-asserted-by":"crossref","unstructured":"Zhang A, Liu Y, Wei S. BCOR mutations in acute myeloid leukemia: clonal evolution and prognosis. Blood. 2020; 136(Suppl 1):4.","DOI":"10.1182\/blood-2020-137127"},{"key":"61896","doi-asserted-by":"crossref","unstructured":"Kumar RD, Searleman AC, Swamidass SJ, Griffith OL, Bose R. Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data. Bioinformatics. 2015; 31(22):3561-3568.","DOI":"10.1093\/bioinformatics\/btv430"},{"key":"61897","doi-asserted-by":"crossref","unstructured":"Schroeder MP, Rubio-Perez C, Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action. Bioinformatics. 2014; 30(17):i549-i555.","DOI":"10.1093\/bioinformatics\/btu467"},{"key":"61898","doi-asserted-by":"crossref","unstructured":"Tiacci E, Grossmann V, Martelli MP. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica. 2012; 97(1):3-5.","DOI":"10.3324\/haematol.2011.057901"},{"key":"61899","doi-asserted-by":"crossref","unstructured":"Montgomery ND, Galeotti J, Johnson SM. Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations. Blood Adv. 2021; 5(24):5612-5616.","DOI":"10.1182\/bloodadvances.2021005308"},{"key":"61900","doi-asserted-by":"crossref","unstructured":"Tefferi A, Mudireddy M, Finke CM. U2AF1 mutation variants in myelodysplastic syndromes and their clinical correlates. Am J Hematol. 2018; 93(6):E146-E148.","DOI":"10.1002\/ajh.25084"},{"key":"61901","doi-asserted-by":"crossref","unstructured":"Pritzl SL, Gurney M, Badar T. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis-a prospective Mayo Clinic cohort study. Leuk Res. 2023; 125:107007.","DOI":"10.1016\/j.leukres.2022.107007"},{"key":"61902","doi-asserted-by":"crossref","unstructured":"Song G-Y, Kim T, Ahn S-Y. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia. Bone Marrow Transplant. 2022; 57(12):1810-1819.","DOI":"10.1038\/s41409-022-01817-0"},{"key":"61903","doi-asserted-by":"crossref","unstructured":"Baranwal A, Chhetri R, Yeung D. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant. 2023; 58(7):769-776.","DOI":"10.1038\/s41409-023-01970-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284185\/76592","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284185\/77058","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11430\/76592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:37Z","timestamp":1794045937000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284185","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}